Many cancer drugs impact cancer cell redox regulatory mechanisms and disrupt redox homeostasis. Pharmacodynamic biomarkers that measure therapeutic efficacy or toxicity could improve patient management. Using immunoblot analyses and mass spectrometry, we identified that serpins A1 and A3 were S-glutathionylated in a dose-and time-dependent manner following treatment of mice with drugs that alter reactive oxygen or nitrogen species.
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Introduction
Preclinical and early clinical testing of novel anticancer drugs can be significantly enabled by the inclusion of direct or surrogate biomarkers that correlate with pharmacological effects (1, 2) . Incorporation of such biomarkers can enhance data interpretation, provide an explanation for either positive or negative correlations with efficacy or toxicity and aid in early decision candidate selection. In complex diseases such as cancer, recent trends in drug development have moved towards targeted therapies to provide maximal therapeutic response while minimizing side effects. Failure of early stage clinical trials incurs great expense and there is merit in including biomarkers, both to estimate treatment efficacy and to identify patients with phenotypic characteristics that might predict response outcomes or toxicities.
In evaluating drug response, a single biomarker can lend itself to quantitative measurements through dose and time response studies. The metabolism of many drugs leads to production of electrophilic species that can generate reactive oxygen or nitrogen species (ROS; RNS). These can directly influence redox balance in both blood and tissue compartments. Biological "sensing" of redox changes is most actively monitored through select cysteine residues in various proteins. While there is debate as to the precise definition of what constitutes redox "sensing" versus redox "signaling" (3) there is little doubt that cysteines at various oxidation states are integral. S-glutathionylation is a post-translational modification that occurs when a cysteine in a low pK environment forms a disulfide bond with GS -. This is reversible and the resultant Ͷ S-glutathionylation cycle has the potential to selectively regulate the function of numerous enzymes, receptors, structural proteins, transcription factors, and transport proteins. Moreover, post-translational modification may alter a variety of protein-protein interactions (4) . The activities of serine protease inhibitors (serpins) are regulated by modifications of key cysteines (5, 6) , where for example, S-glutathionylation of serpin A1 results in conformational changes that weaken its affinity for its target protease thereby reducing its effectiveness in preventing proteolytic activity (7) .
Vertebrate serpins are classified into six sub-groups and represent ~2% of the total protein in human plasma (8) . While most are defined by their inhibitory activities, certain serpins have non-inhibitory roles as hormone transporters (9) , molecular chaperones(10) or tumor suppressors (11) . Moreover, serpins can influence myeloproliferation and hematopoetic progenitor cell mobilization.
Serpins A1 and A3 have redox-sensitive cysteines and are down-regulated in bone marrow during mobilization of hematopoetic progenitor cells into the peripheral bloodstream (12) , implicating a regulatory function for Sglutathionylation and redox homeostasis in the marrow compartment. This is consistent with the fact that certain redox active drugs (including the glutathione disulfide mimetic NOV-002 (13) and the GSH peptidomimetic, Telintra (14) ) have both preclinical and clinical myeloproliferative effects (15) .
In the present study we have identified the S-glutathionylation of plasma serpins A1 and A3 as potential quantifiable response biomarkers for assessing response to two different types of drugs that either directly or indirectly impact ͷ redox status. NOV-002 is a formulation of disodium glutathione disulfide (GSSG) that in combination protocols is in Phase II trials for the treatment of breast cancer. NOV-002 causes a redox regulation of protein thiols that persists in plasma for ~4hrs and in rodents and humans stimulates proliferation of bone marrow progenitor cells (13) . PABA/NO is a diazeniumdiolate that acts as a direct nitrogen monoxide (NO) donor and is in development as an anticancer drug. We show that plasma serpin S-glutathionylation correlates with drug treatment in vivo and in vitro. Furthermore, analysis of cancer patient plasma samples suggests disease specific variation in unmodified and S-glutathionylated serpin profiles correlating with drug concentrations.
Materials and Methods
Reagents
Reduced GSH was from Sigma (St. Louis, MO). NOV-002 provided by Novelos Therapeutics (Newton, MA), PABA/NO from Dr. Larry Keefer (16, 17) .
Animal and human plasma studies
Mice were treated with an intravenous bolus of 25mg/kg NOV-002 and after 1h blood was collected via orbital bleed in heparin-coated tubes. Plasma was separated by centrifugation and proteins separated on SDS-PAGE and transferred for immunoblot analyses. Human blood samples were obtained with informed consent from 8 cancer-free volunteers and 47 oncology patients with 
Immunoblot analysis
Equal amounts of purified recombinant serpins A1/A3 or total plasma Simultaneously separated plasma S-glutathionylated protein bands were isolated from gels run simultaneously with immunoblots and trypsin digested.
Identification of S-glutathionylated plasma proteins
Peptide mass was analyzed by matrix-assisted laser desorption/ionization, timeof-flight (MALDI-TOF) mass spectrometry at the Proteomics Core Facility. Protein identification was performed using software from the NCBI protein database.
Immunoprecipitation
Human plasma samples (2mg) were treated with 50μM of NOV-002 for 60min at 37°C. Biotinylated rabbit polyclonal antibodies to serpins A1 and A3 (Abcam, 5μg) were used to pull-down respective proteins by overnight incubations at 4°C. Antibody complexes were isolated through incubation with NeutrAvidin agarose resin (Thermo Scientific) for 2hrs. Resin-bound complexes were washed 5x with immunoprecipitation buffer (20mM HEPES, 300mM NaCl, 1% Triton, 10% glycerol) and proteins eluted in non-reducing SDS-sample buffer.
Immunoprecipitated proteins were separated by non-reducing SDS-PAGE and Sglutathionylation of serpins A1 and A3 evaluated by immunoblot.
In vitro S-glutathionylation assays
Purified serpin A1 or A3 (50ng) was incubated at 37°C in 50mmol/L potassium phosphate buffer (pH 7.2), 1mmol/L GSH with either NOV-002 or PABA/NO. Samples were run on non-reducing SDS-PAGE gels for subsequent transfer and immunoblot analysis. 
Spectroscopic Analysis of Serpin A1 and A3 in vitro
The effect of serpin S-glutathionylation on enzyme secondary structure was examined by circular dichroism (CD) measurements carried out on a 202 AVIV Associates CD spectrometer (Lakewood, NJ) using a semi-micro quartz rectangular 1×10×40mm cuvette. Serpins A1 and A3 (~2mg/ml) were Sglutathionylated by treatment with 40μmol/L PABA/NO and 1mM GSH for 30min in 20mM PB, pH 7.4, at 37°C. Excess PABA/NO and GSH were eliminated using Biospin-6 (Bio-Rad) SEC micro-spin columns.
Purified native and S-glutathionylated serpins A1 and A3 (~95% homogeneous, 40μM in 20mM PB, pH 7.4) were maintained at 22°C using a Background spectra were subtracted from final emission data.
Statistical Analyses
Statistical analyses were performed using GraphPad Prism (GraphPad Software, San Diego, CA, USA). P-values lower than 0.05 were considered significant. Parametric data were statistically evaluated using T-tests and nonparametric data were evaluated using Mann-Whitney or Wilcoxon matched-pairs signed rank test tests, based on data distribution. Multiple comparisons were analyzed using ANOVAs with Dunnett's Multiple Comparison tests or KruskallWallis tests with Dunn's multiple Comparsion test. Corrections were applied based on program recommendation. Relative S-glutathionylation levels induced in cancer were analyzed using Two-Way ANOVAs.
Results
In vivo treatment with NOV-002, leads to S-glutathionylation of a limited sub-set of plasma proteins in mice ( Purified recombinant A1 and A3 protein was treated in vivo and in vitro with agents known to induce protein S-glutathionylation (13, 19) . In the presence of PABA/NO and GSH, both serpins A1 and A3 were S-glutathionylated in a time- (Figure 2A ) and concentration-dependent manner ( Figure 2B ). Serpin A1 was rapidly S-glutathionylated within 1min and peaked at approximately 5-10min.
Following this, S-glutathionylated protein levels gradually declined. Alternatively, serpin A3 showed a more gradual increase in S-glutathionylation over a 30min time course, suggesting unique protein properties despite high sequence homology. Similar drug concentrations were needed to induce minimum (at ~25μmol/L PABA/NO) and maximum (at ~75μmol/L PABA/NO) Sglutathionylation levels of both serpins A1 and A3. However, drug-induced Sglutathionylation levels of serpin A3 became relatively saturated between 25 and 50μmol/L PABA/NO, suggesting that serpin A3 S-glutathionylation may be more time-dependent. We evaluated the effects of S-glutathionylation on serpin secondary structure. Tryptophanyl fluorescence of serpin A3 was lower than that ͳʹ of serpin A1 indicating a quenching in the former. Tryptophanyl fluorescence of S-glutathionylated serpin A3 had an increased intensity and a shift of emission maximum from 328 to 336nm, interpreted as tryptophanyl exposure to a more polar environment, decrease of quenching and structural change (Fig. 2C) . The CD spectrum (far UV, 190-260nm) of S-glutathionylated serpin A1 was similar to that of native protein, consistent with a minimal increase in the Į-helical content (206-220nm) of the protein (Fig. 2D ). This suggests a minor decrease in tryptophanyl fluorescence caused by S-glutathionylation, indicating a reasonably intact tertiary and quaternary structure. In contrast, the CD spectrum of Sglutathionylated serpin A3 was distinct from that of the native protein, consistent with an increase in the ȕ-strand content of the protein and altered protein folding (Fig. 2D) . These fluorescent analyses confirm that S-glutathionylation affects the tertiary structure of serpin A3.
S-glutathionylated recombinant serpins A1 and A3 were analyzed using tandem mass spectrometry in order to identify S-glutathionylated cysteines.
Purified recombinant serpins A1 and A3 were incubated at 37°C for 30min the presence of 100μmol/L PABA/NO and 10mmol/L GSH.
Analyses of (RLGMFNIQHCK) of serpin A1 (Fig. 3A,B Figure 3D ). These data provide a platform to develop analytical methods for quantification of S-glutathionylated serpins in biological fluids.
Human plasma samples from 47 cancer patients undergoing chemotherapy treatments and 8 cancer-free patients were analyzed for total and S-gluathionylated serpin A1 and A3 protein. Immunoblot densitometry showed significantly (P<0.05) elevated amounts of each unmodified serpin in cancer patients (Fig. 4A, 4B ). All protein bands were normalized to an albumin loading control as well as an internal standard, permitting comparison across membranes. Levels of S-glutathionylated serpins A1 and A3 did not correlate with total serpin levels. In fact, serpin S-glutathionylation profiles were distinct between patients suggesting that individual patients with specific disease and treatment profiles have unique serpin S-glutathionylation. However, when analyzing all cancers in a group, the overall ratio of S-glutathionylated serpin A1 (PSSGa and PSSGc) and A3 (PSSGb) to unmodified serpin A1 and A3, respectively, was significantly decreased (P<0.05) in cancer patients (Fig. 4C) .
Thus, in reference to the total amount of serpin, the fraction of serpin protein subject to S-glutathionylation was lower in cancer patients. Table 1 and PSSGc/A1) in cancer-free plasma as compared to cancer patients (Fig. 5C ).
Thus, in response to treatment, serpin S-glutathionylation and disease status are interrelated and demonstrate altered redox homeostasis in cancer patients. NOV-002 treatment also induced S-glutathionylation of albumin, as evidenced by the doublet band was detected only at high drug concentrations. Critically, NOV-002 treatment did not alter serpin stability, as indicated by total serpin immunoblotting. Treatment with 40μmol/L NOV-002 for 0-240min did not change levels of unmodified serpin A1 or A3 (P>0.05) (Fig. 5D ). Additional analyses using treated and untreated plasma samples from cancer and cancer-free ͳͷ patients support these data (Fig. 5E) . Treatment with Velcade, vinblastine, Taxol, or tamoxifen did not induce changes in plasma serpin A1 or A3 Sglutathionylation (Supplemental Data, Fig. 2A , B, C and D).
GSTP and Grx1 are involved in the forward and reverse reactions of Sglutathionylation. Relative protein levels were determined via densitometry and then normalized to an albumin loading control, as well as an internal standard incorporated into all gels. Plasma protein levels of GSTP were significantly decreased (P<0.05) in cancer patients as compared to cancer-free. Conversely, plasma Grx1 levels were significantly elevated (P<0.05) in cancer patients (Fig   6) . These data are consistent with the interpretation that the decreased relative ratio of S-glutathionylated to unmodified serpin in cancer patient plasma may be linked with diminished GSTP levels and a relatively enhanced rate of serpin deglutathionylation, as a consequence of elevated Grx1.
Discussion
There is expanding interest in adopting a redox-modulating platform in drug discovery/development in cancer (20) . In this study we used two drugs that alter redox homeostasis through distinct mechanisms. NOV-002 is an oxidized glutathione mimetic that modifies extra-and intracellular ratio of GSH:GSSG (13, 21) . PABA/NO releases NO to raise levels of RNS and ROS (19) . However, the present data provide are the first to report a similar redox-sensitive cysteine in serpin A3. Oxidation of cysteine residues in serpins inhibits their activity (7, (24) (25) (26) . Our patient profile data showed that baseline protein levels of both serpin A1 and A3 were elevated in the plasma of cancer patients. Elevated serpin A1 expression in tumors has been correlated with poor prognosis and highly invasive, metastatic adenocarcinomas (34) (35) (36) and with poor response in multiple myleoma (37) . While the functional importance of serpins A1 and A3 in cancer is not yet clearly defined, serpin A1 has inhibitory activity against cytotoxic T lymphocytes and natural killer cells (38) , suggesting that the tumor-promoting effect of serpin A1 could be related to a decreased immune response against malignant cells. Serpin A1 overexpression may also be a useful biomarker in insulinomas (39) . In leukemias, where the cancer is of bone marrow origin, further defining a role of serpin A1 and A3 S-glutathionylation in myeloproliferation may be valuable with regards to development of tailored treatment strategies. Chronic oxidative stress, characterized by excessive cellular ROS levels, occurs in several hematopoietic malignancies including ALL, MDS, CML, and AML (40) (41) (42) 
